Dare Bioscience logo

Dare BioscienceNASDAQ: DARE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 April 2014

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$28.28 M
-83%vs. 3y high
28%vs. sector
-vs. 3y high
-vs. sector
-19.05
-204%vs. 3y high
2%vs. sector
-70%vs. 3y high
83%vs. sector

Price

after hours | Wed, 20 Nov 2024 23:44:50 GMT
$3.25+$0.07(+2.20%)

Dividend

No data over the past 3 years
$41.70 K$1.00 M
$41.70 K-$4.70 M

Analysts recommendations

Institutional Ownership

DARE Latest News

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript
seekingalpha.com14 November 2024 Sentiment: POSITIVE

Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conference Call Participants Catherine Novack - JonesTrading Brian Kemp Dolliver - Brookline Capital Markets Douglas Tsao - H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the company's Third Quarter Financial Results and to provide a general business update.

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
zacks.com14 November 2024 Sentiment: NEUTRAL

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $1.08 per share a year ago.

Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know
zacks.com07 November 2024 Sentiment: POSITIVE

Dare Bioscience (DARE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health
globenewswire.com23 October 2024 Sentiment: POSITIVE

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management.

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
globenewswire.com21 October 2024 Sentiment: POSITIVE

Provides Daré access to capital at Daré's discretion with any proceeds available to help fund portfolio advancement, such as the Phase 3 program for Sildenafil Cream, 3.6%, a potential first-in-category treatment for female sexual arousal disorder using the same active ingredient as in Viagra® Provides Daré access to capital at Daré's discretion with any proceeds available to help fund portfolio advancement, such as the Phase 3 program for Sildenafil Cream, 3.6%, a potential first-in-category treatment for female sexual arousal disorder using the same active ingredient as in Viagra®

Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates
zacks.com12 August 2024 Sentiment: POSITIVE

Dare Bioscience, Inc. (DARE) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of a loss of $0.57 per share. This compares to loss of $1.20 per share a year ago.

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
globenewswire.com12 August 2024 Sentiment: POSITIVE

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder continued operational progress toward a planned Phase 3 study; additional FDA feedback forthcoming; Phase 3 design, development, and collaboration strategy updates SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended June 30, 2024 and provided a company update.

Daré Bioscience Announces Reverse Stock Split
globenewswire.com27 June 2024 Sentiment: POSITIVE

Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split of the issued shares of its common stock, effective at 12:01 a.m. Eastern Time on July 1, 2024.

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
Seeking Alpha28 March 2024 Sentiment: POSITIVE

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript
Seeking Alpha09 November 2023 Sentiment: NEUTRAL

Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Commercial Officer Lisa Walters-Hoffert - CFO Conference Call Participants Catherine Novack - Jones Trading Doug Tsao - H.C. Wainright Operator Welcome to the conference hosted by Daré Bioscience to Review the Company's Third Quarter Financial Results and to provide a General Business Update.

What type of business is Dare Bioscience?

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

What sector is Dare Bioscience in?

Dare Bioscience is in the Healthcare sector

What industry is Dare Bioscience in?

Dare Bioscience is in the Biotechnology industry

What country is Dare Bioscience from?

Dare Bioscience is headquartered in United States

When did Dare Bioscience go public?

Dare Bioscience initial public offering (IPO) was on 10 April 2014

What is Dare Bioscience website?

https://darebioscience.com

Is Dare Bioscience in the S&P 500?

No, Dare Bioscience is not included in the S&P 500 index

Is Dare Bioscience in the NASDAQ 100?

No, Dare Bioscience is not included in the NASDAQ 100 index

Is Dare Bioscience in the Dow Jones?

No, Dare Bioscience is not included in the Dow Jones index

When was Dare Bioscience the previous earnings report?

No data

When does Dare Bioscience earnings report?

The next expected earnings date for Dare Bioscience is 28 March 2025